Skip to main content
editorial
. 2018 Feb 19;17(3):269–270. doi: 10.1080/15384101.2017.1408229

Figure 1.

Figure 1.

Under conditions of partial therapeutic response, tumour CICD can have two anti-cancer effects. Engaging MOMP-under caspase inhibited conditions triggers cell death and anti-tumour immunity dependent upon NFκB in the dying cell. Anti-tumour immunity can kill remaining tumour cells.